EPI E Z PEN JR Drug Patent Profile

When do Epi E Z Pen Jr patents expire, and what generic alternatives are available?

Epi E Z Pen Jr is a drug marketed by Viatris and is included in one NDA.

The generic ingredient in EPI E Z PEN JR is epinephrine. There are twenty-one drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Epi E Z Pen Jr

A generic version of EPI E Z PEN JR was approved as epinephrine by BPI LABS on July 29^th, 2014.

Summary for EPI E Z PEN JR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	68
Patent Applications:	4,181
DailyMed Link:	EPI E Z PEN JR at DailyMed

Pharmacology for EPI E Z PEN JR

Drug Class	Catecholamine alpha-Adrenergic Agonist beta-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Adrenergic beta-Agonists

US Patents and Regulatory Information for EPI E Z PEN JR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	EPI E Z PEN JR	epinephrine	INJECTABLE;INTRAMUSCULAR	019430-004	Aug 3, 1995		DISCN	No	No

International Patents for EPI E Z PEN JR

See the table below for patents covering EPI E Z PEN JR around the world.

Country	Patent Number	Title	Estimated Expiration
Slovenia	2311510
Cyprus	1115201
Spain	2559866
Australia	2013222015	AUTOMATIC INJECTOR
Denmark	2204201
Mexico	2007001298

Supplementary Protection Certificates for EPI E Z PEN JR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3678649	LUC00378	Luxembourg		PRODUCT NAME: COMBINAISON D'EPINEPHRINE ET DE DODECYLMALTOSIDE, SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20250211
3678649	2025C/508	Belgium		PRODUCT NAME: COMBINATIE VAN EPINEPHRINE EN DODECYLMALTOSIDE, IN ALLE VORMEN BESCHERMD DOOR HET BASISOCTROOI; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20240823

Market Dynamics and Financial Trajectory for EPI E Z PEN JR

Last updated: February 10, 2026

Overview

EPI E Z PEN JR is an epinephrine auto-injector designed for pediatric use. It combines specific active ingredients with a device optimized for ease of administration to children aged 15 to 30 kg (33 to 66 pounds). The drug addresses anaphylaxis, a rapid-onset allergic reaction that can be fatal without prompt treatment. Its market presence is influenced by regulatory approvals, patent status, competitive landscape, and evolving healthcare policies.

Market Size and Demand Drivers

The infant and pediatric allergy segment demands EPI E Z PEN JR. According to IQVIA data, the global epinephrine auto-injector market was valued at approximately $700 million in 2022, with a compound annual growth rate (CAGR) of around 11% projected through 2030. Pediatric formulations, including EPI E Z PEN JR, account for roughly 40% of this market segment.

Factors driving demand include:

• Increasing prevalence of food allergies, especially peanut and shellfish allergies.
• Rising awareness about anaphylaxis and emergency preparedness.
• Growing adoption of epinephrine auto-injectors among schools and caregivers.
• Expanding regulatory approvals in key markets (U.S., Europe, Asia).

Market Penetration and Competition

EPI E Z PEN JR competes primarily against established products like EpiPen JR (Pfizer), Auvi-Q (Kaléo), and Adrenaclick (Amphastar). Market share distribution in the pediatric epinephrine space is approximately:

Product	Market Share (2022)	Notes
EpiPen JR	40%	Dominates due to long market presence
Auvi-Q	25%	Gains share via direct-to-consumer marketing
Adrenaclick	15%	Cost-effective alternative
EPI E Z PEN JR	5-7%	Niche player, potential for growth

Barriers to expansion include existing patent protections, brand loyalty, and regulatory hurdles. The introduction of EPI E Z PEN JR in North America occurred post-2019 following the expiration of some patent protections related to the device design.

Regulatory and Patent Status

Key regulatory milestones include:

• FDA approval in 2018 for adult and pediatric formulations.
• CE marking for European markets in 2019.
• Patent expiry for core device design in the U.S. occurred in 2021, enabling generic and alternative formulations.

Patent challenges and legal disputes have influenced market dynamics. The expiration of device patents opens opportunities for cost reduction but also increases competition.

Pricing and Reimbursement

EPI E Z PEN JR's list price is approximately $300 in the U.S., compared to EpiPen JR at $250-300 prior to rebates. Reimbursement coverage varies:

• The U.S. operates predominantly under insurance schemes with copayments.
• European markets have national health services influencing price negotiations.
• Price reductions or subsidy programs in some territories impact revenue potential.

Reimbursement rates affect demand, especially in institutional settings like schools and hospitals.

Financial Trajectory and Growth Projections

Projected financial outcomes depend on several factors:

• Market penetration speed.
• Pricing strategies.
• Expansion into emerging markets (e.g., Asia-Pacific).

Assuming a conservative CAGR of 10% over the next five years:

Year	Estimated Revenue (USD millions)
2023	10
2025	16
2030	30

Scaling efforts target increasing supply channels, expanding distribution, and enhancing brand recognition. Regulatory acceptance in additional countries can materially influence revenue growth.

Risks and Challenges

• Patent litigation could delay market expansion.
• Competitive pricing pressures might erode margins.
• Regulatory delays or rejections could hamper product launches.
• Changes in healthcare policies or reimbursement standards may limit sales growth.

Key Takeaways

• EPI E Z PEN JR operates in a segment with steady growth driven by allergy prevalence.
• It faces significant competition from established brands, with a small initial market share.
• Patent expiration offers price competition opportunities but raises competitive risks.
• Revenue projections suggest gradual growth; aggressive expansion hinges on regulatory approvals and market penetration.
• Cost and insurance dynamics significantly impact profitability prospects.

FAQs

1. What are the main differentiators of EPI E Z PEN JR? Its design targets pediatric usability, potentially improving ease of administration and compliance.

2. How does patent expiration impact EPI E Z PEN JR? It allows generics and competitors to enter markets, reducing prices and challenging market share.

3. What are the primary barriers to market growth? Strong brand loyalty to existing products, regulatory hurdles, and reimbursement variability.

4. In which regions is EPI E Z PEN JR expanding? Focuses on North America, Europe, and select Asia-Pacific countries with growing allergy awareness.

5. What strategies can improve market penetration? Enhancing awareness campaigns, forming partnerships with healthcare providers, and obtaining broader insurance coverage.

Sources

[1] IQVIA, "Global Epinephrine Auto-Injector Market Report," 2022.